An interventional study of Oral glutamine supplementation and Oral protein powder supplementation in Obesity and Insulin Resistance, sponsored by University Hospital, Rouen. Recruiting at 1 site in France. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-02-06.
Sponsored by University Hospital, Rouen · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 476 studies in Obesity with a site in France — 112 open to participants now, 128 under way, 25 of them phase 3. Obesity · France.
Among the 476 studies in Obesity with a site in France, this one is the 147th largest by planned enrollment of the 355 interventional ones that give a count, is one of 25 that started in 2023, is one of 259 with no phase, reaches primary completion later than 26 of the 127 other live ones, and was the 324th registered.
11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.
Browse Obesity studies →112 of the 476 studies in Obesity with a site in France are open now. Recruiting first, the newest first:
Nantes University Hospital · Sites in France
Ages 18+
Laboratoire des Adaptations Métaboliques à l'Exercice en conditions Physiologiques et Pathologiques · Sites in France
Ages 50–75
AstraZeneca · Sites in France, United States, Argentina and 13 more countries
Ages 18+
Novo Nordisk A/S · Sites in France, United States, Belgium and 7 more countries
Ages 18+
Hospices Civils de Lyon · Sites in France
Ages 18–75
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
476 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 21 · Phase 3 61 · Phase 4 14
First in 2001; this study’s year is marked. 25 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 110 is above the median of 67 across 9,043 interventional studies indexed under Obesity.
Median enrollment 80 across the 355 interventional studies, 133 across the 121 observational. Of the 295 that completed or were terminated, 16 (5%) have results posted.
This tab as a report to print or save as PDF → With an account.
76 of 476 have an industry lead sponsor. The 10 most frequent:
University Hospital, Rouen is the lead sponsor of 418 studies on the registry; 106 are open to participants now.
University Hospital, Rouen has 8 studies filed under Obesity — fewer than ten, so there is no comparison to draw.
31 of the studies in Obesity with a site in France that are under way reach primary completion within a year, 8 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06914895Phase 3Eli Lilly and CompanyA Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight | 2026-11 |
| NCT06962280Phase 3Eli Lilly and CompanyA Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight | 2026-11 |
| NCT03516968Phase 3Hospices Civils de LyonMonthly Boluses Versus Daily Doses for Correcting Blood Vitamin D Deficit in Obese Children and Adolescents | 2027-03 |
| NCT07220642Phase 3Novo Nordisk A/SWeight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide | 2027-05-11 |
| NCT07225686Phase 3AmgenMaridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy | 2027-08-20 |
Add all 31 to your calendar (.ics) → With an account.
Among the 476 studies in Obesity with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Obesity, which has a prevalence at 15% in France, is a major public health concern. Altered glycemic control and irritable bowel syndrome (IBS) are frequently observed in obese patients and lead to reduce the quality of life. In the last decades, the role of gut microbiota and intestinal permeability has been underlined in obesity, glycemic control and IBS. Interestingly, experimental and clinical data show that glutamine, an amino acid, is able to maintain or restore intestinal permeability in different conditions. We thus hypothesize that oral glutamine supplementation may restore gut barrier function contributing to improve glycemic control and IBS-symptoms. Our project will thus aim to evaluate the effects of 8 weeks - oral glutamine supplementation on glycemic control and IBS symptoms in obese patients in a blinded randomized controlled trial. Placebo group will received protein powder. 55 obese patients will enrolled in each arm and will received oral glutamine supplementation or protein powder (10g t.i.d.) during 8 weeks. Blood and feces samples and intestinal permeability assays will be performed at baseline (w0), after 8 weeks of supplementation (w8) and then after 8 weeks of a wash-out period (w16).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
patient will receive Oral glutamine supplementation 10 g Ter In Die during 8 weeks
Dietary Supplement: Oral glutamine supplementation · Procedure: Insulin-resistance evaluation · Procedure: Functional intestinal disorders evaluation
patient will receive Oral protein powder supplementation10 g Ter In Die during 8 weeks
Dietary Supplement: Oral protein powder supplementation · Procedure: Insulin-resistance evaluation · Procedure: Functional intestinal disorders evaluation
patient will receive oral glutamine supplementation 10 g Ter In Die during 8 weeks
patient will receive oral protein powder supplementation10 g Ter In Die during 8 weeks
Homeostasic model assessment of insulin resistance test will be performed at baseline, Week 8 and Week 16
Functional intestinal disorders will be measured by the IBS severity score and feces consistency by Bristol scale at baseline, Week 8 and Week 16
Change between Homeostasic model assessment of insulin resistance test value at baseline and week 8
Time frame: Week 8
Change between Homeostasic model assessment of insulin resistance test value at baseline and week 16
Time frame: Week 16
Change between Homeostasic model assessment of insulin resistance test value at Week 8 and week 16
Time frame: week 16
Change between Irritable Bowel Syndrome (IBS) severity score at baseline and week 8
Francis score will be used
Time frame: Week 8
Change between Irritable Bowel Syndrome (IBS) severity score at baseline and week 16
Francis score will be used
Time frame: Week 16
Change between feces consistency at baseline and week 8
bristol scale will be used
Time frame: Week 8
Change between feces consistency at baseline and week 16
bristol scale will be used
Time frame: Week 16
Plan to share: No
No publications or documents are linked to this record.
Started Mar 2023 (actual). Primary completion is estimated for Jun 2026, 39 months after the start.
Of 3,697 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 39 months is above that.
Counting every sponsor, half of 3,861 studies reached it within 22 months; a quarter within 9 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.